FI69465C - Foerfarande foer framstaellning av farmakologiskt aktiva 3,8-dialkylxantiner - Google Patents
Foerfarande foer framstaellning av farmakologiskt aktiva 3,8-dialkylxantiner Download PDFInfo
- Publication number
- FI69465C FI69465C FI811212A FI811212A FI69465C FI 69465 C FI69465 C FI 69465C FI 811212 A FI811212 A FI 811212A FI 811212 A FI811212 A FI 811212A FI 69465 C FI69465 C FI 69465C
- Authority
- FI
- Finland
- Prior art keywords
- ethyl
- dihydro
- purine
- dione
- propyl
- Prior art date
Links
- 230000000144 pharmacologic effect Effects 0.000 title description 4
- 235000013399 edible fruits Nutrition 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims abstract description 8
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 6
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims abstract description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 239000013078 crystal Substances 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 229960000278 theophylline Drugs 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- QHEMDIZENXAVRQ-UHFFFAOYSA-N 6-amino-1-ethylpyrimidine-2,4-dione Chemical compound CCN1C(N)=CC(=O)NC1=O QHEMDIZENXAVRQ-UHFFFAOYSA-N 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- KTWOUYVBZDZRNV-UHFFFAOYSA-N 6-amino-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=CC(=O)NC1=O KTWOUYVBZDZRNV-UHFFFAOYSA-N 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- HEXZSEOAILCDMD-UHFFFAOYSA-N 5,6-diamino-1-ethylpyrimidine-2,4-dione Chemical compound CCN1C(N)=C(N)C(=O)NC1=O HEXZSEOAILCDMD-UHFFFAOYSA-N 0.000 description 7
- SHKJXAPOAVPNKW-UHFFFAOYSA-N 6-amino-1-ethyl-5-nitrosopyrimidine-2,4-dione Chemical compound CCN1C(N)=C(N=O)C(=O)NC1=O SHKJXAPOAVPNKW-UHFFFAOYSA-N 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- -1 n-propyl-t-butyl Chemical group 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- AHSKLSFFKJHWAI-RGMNGODLSA-N (2s)-2-amino-5-[[amino(dimethylamino)methylidene]amino]pentanoic acid;hydrochloride Chemical compound Cl.CN(C)C(N)=NCCC[C@H](N)C(O)=O AHSKLSFFKJHWAI-RGMNGODLSA-N 0.000 description 6
- CLRHVOHIFNLQBD-UHFFFAOYSA-N 3-ethyl-8-methyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1NC(C)=N2 CLRHVOHIFNLQBD-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- CESVXSGKVYVAIY-UHFFFAOYSA-N 8-ethyl-3-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1NC(CC)=N2 CESVXSGKVYVAIY-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- USJZZQWWJAQGQQ-UHFFFAOYSA-N 3,8-diethyl-7h-purine-2,6-dione Chemical compound CCN1C(=O)NC(=O)C2=C1N=C(CC)N2 USJZZQWWJAQGQQ-UHFFFAOYSA-N 0.000 description 4
- YOMSKQSCRYRZDC-UHFFFAOYSA-N 5,6-diamino-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=C(N)C(=O)NC1=O YOMSKQSCRYRZDC-UHFFFAOYSA-N 0.000 description 4
- PJHVUYYGBOUXNX-UHFFFAOYSA-N 6-amino-5-nitroso-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=C(N=O)C(=O)NC1=O PJHVUYYGBOUXNX-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000414 obstructive effect Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KPCXHYGABMLZIK-UHFFFAOYSA-N 3,8-dipropyl-7h-purine-2,6-dione Chemical compound CCCN1C(=O)NC(=O)C2=C1N=C(CCC)N2 KPCXHYGABMLZIK-UHFFFAOYSA-N 0.000 description 2
- QPHOMKKIIXKEFJ-UHFFFAOYSA-N 3-(2,2-dimethylpropyl)-8-ethyl-7h-purine-2,6-dione Chemical compound CC(C)(C)CN1C(=O)NC(=O)C2=C1N=C(CC)N2 QPHOMKKIIXKEFJ-UHFFFAOYSA-N 0.000 description 2
- HNCVLKPKADKQRS-UHFFFAOYSA-N 3-(cyclohexylmethyl)-8-ethyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(CC)=NC=2N1CC1CCCCC1 HNCVLKPKADKQRS-UHFFFAOYSA-N 0.000 description 2
- QGQYTYQGUZHPRN-UHFFFAOYSA-N 3-butyl-8-ethyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCC)C2=C1NC(CC)=N2 QGQYTYQGUZHPRN-UHFFFAOYSA-N 0.000 description 2
- SLCXXNSWUYKYPG-UHFFFAOYSA-N 3-cyclopropyl-8-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(CCC)=NC=2N1C1CC1 SLCXXNSWUYKYPG-UHFFFAOYSA-N 0.000 description 2
- OOYNVMRTNHKXKH-UHFFFAOYSA-N 3-ethyl-8-(2-methylpropyl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1NC(CC(C)C)=N2 OOYNVMRTNHKXKH-UHFFFAOYSA-N 0.000 description 2
- WSASYFRNDGIHPI-UHFFFAOYSA-N 3-ethyl-8-propan-2-yl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1NC(C(C)C)=N2 WSASYFRNDGIHPI-UHFFFAOYSA-N 0.000 description 2
- JFUQVWKKZAYRSJ-UHFFFAOYSA-N 3-ethyl-8-propyl-7h-purine-2,6-dione Chemical compound CCN1C(=O)NC(=O)C2=C1N=C(CCC)N2 JFUQVWKKZAYRSJ-UHFFFAOYSA-N 0.000 description 2
- FKEKRSDFADVUIR-UHFFFAOYSA-N 8-butyl-3-ethyl-7h-purine-2,6-dione Chemical compound CCN1C(=O)NC(=O)C2=C1N=C(CCCC)N2 FKEKRSDFADVUIR-UHFFFAOYSA-N 0.000 description 2
- PNQAEUAKVKPMTF-UHFFFAOYSA-N 8-butyl-3-propyl-7h-purine-2,6-dione Chemical compound CCCN1C(=O)NC(=O)C2=C1N=C(CCCC)N2 PNQAEUAKVKPMTF-UHFFFAOYSA-N 0.000 description 2
- PMQWRMJBBJNEMM-UHFFFAOYSA-N 8-cyclobutyl-3-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCC)C=2N=C1C1CCC1 PMQWRMJBBJNEMM-UHFFFAOYSA-N 0.000 description 2
- SYRHESIAEYBQNC-UHFFFAOYSA-N 8-ethyl-3-(2-methylbutyl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CC(C)CC)C2=C1NC(CC)=N2 SYRHESIAEYBQNC-UHFFFAOYSA-N 0.000 description 2
- MJZJLHAIWFTNNB-UHFFFAOYSA-N 8-ethyl-3-(2-methylpropyl)-7h-purine-2,6-dione Chemical compound CC(C)CN1C(=O)NC(=O)C2=C1N=C(CC)N2 MJZJLHAIWFTNNB-UHFFFAOYSA-N 0.000 description 2
- DYDNLUOQZZAUEZ-UHFFFAOYSA-N 8-ethyl-3-(3-methylbutyl)-7h-purine-2,6-dione Chemical compound CC(C)CCN1C(=O)NC(=O)C2=C1N=C(CC)N2 DYDNLUOQZZAUEZ-UHFFFAOYSA-N 0.000 description 2
- CNVJBOYEHORNLI-UHFFFAOYSA-N 8-propan-2-yl-3-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1NC(C(C)C)=N2 CNVJBOYEHORNLI-UHFFFAOYSA-N 0.000 description 2
- HWYGLJMXISRPOR-UHFFFAOYSA-N 8-tert-butyl-3-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1NC(C(C)(C)C)=N2 HWYGLJMXISRPOR-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- ZQZJKHIIQFPZCS-UHFFFAOYSA-N propylurea Chemical compound CCCNC(N)=O ZQZJKHIIQFPZCS-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- WDLAKCAOEKLEIV-UHFFFAOYSA-N 3-cyclobutyl-8-ethyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(CC)=NC=2N1C1CCC1 WDLAKCAOEKLEIV-UHFFFAOYSA-N 0.000 description 1
- DZXAEJCKQAXDGM-UHFFFAOYSA-N 3-cyclopentyl-8-ethyl-7H-purine-2,6-dione Chemical compound C1(CCCC1)N1C(NC(C=2NC(=NC12)CC)=O)=O DZXAEJCKQAXDGM-UHFFFAOYSA-N 0.000 description 1
- SAHWVZACGUPTQJ-UHFFFAOYSA-N 3-cyclopropyl-8-ethyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(CC)=NC=2N1C1CC1 SAHWVZACGUPTQJ-UHFFFAOYSA-N 0.000 description 1
- QDHPVYJXCHOBBC-UHFFFAOYSA-N 6-amino-1-ethyl-5-nitropyrimidine-2,4-dione Chemical compound CCN1C(N)=C([N+]([O-])=O)C(=O)NC1=O QDHPVYJXCHOBBC-UHFFFAOYSA-N 0.000 description 1
- PDKNBSLTBPMRHQ-UHFFFAOYSA-N 8-(2-methylpropyl)-3-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1NC(CC(C)C)=N2 PDKNBSLTBPMRHQ-UHFFFAOYSA-N 0.000 description 1
- GGOSLMWKWVWOCQ-UHFFFAOYSA-N 8-cyclopropyl-3-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCC)C=2N=C1C1CC1 GGOSLMWKWVWOCQ-UHFFFAOYSA-N 0.000 description 1
- MXNWQDSTCBTICY-UHFFFAOYSA-N 8-ethyl-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCCC)C2=C1NC(CC)=N2 MXNWQDSTCBTICY-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- PUYGPBSOFXYHMH-UHFFFAOYSA-N C(C)C1N=C2N(CNC=C2N1)CCC Chemical compound C(C)C1N=C2N(CNC=C2N1)CCC PUYGPBSOFXYHMH-UHFFFAOYSA-N 0.000 description 1
- SWGZKGJCCFYJSJ-UHFFFAOYSA-N C(C)C1N=C2N(CNC=C2N1)CCCCC Chemical compound C(C)C1N=C2N(CNC=C2N1)CCCCC SWGZKGJCCFYJSJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical class [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000277284 Salvelinus fontinalis Species 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8002910 | 1980-04-18 | ||
| SE8002910A SE8002910L (sv) | 1980-04-18 | 1980-04-18 | 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI811212L FI811212L (fi) | 1981-10-19 |
| FI69465B FI69465B (fi) | 1985-10-31 |
| FI69465C true FI69465C (fi) | 1986-02-10 |
Family
ID=20340763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI811212A FI69465C (fi) | 1980-04-18 | 1981-04-16 | Foerfarande foer framstaellning av farmakologiskt aktiva 3,8-dialkylxantiner |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4546182A (fr) |
| EP (1) | EP0038784B1 (fr) |
| JP (1) | JPS56166191A (fr) |
| AT (1) | ATE10099T1 (fr) |
| AU (1) | AU543122B2 (fr) |
| CA (1) | CA1156229A (fr) |
| DD (1) | DD158400A5 (fr) |
| DE (1) | DE3166893D1 (fr) |
| DK (1) | DK151631B (fr) |
| ES (1) | ES8203088A1 (fr) |
| FI (1) | FI69465C (fr) |
| GR (1) | GR82347B (fr) |
| HU (1) | HU185254B (fr) |
| IE (1) | IE51106B1 (fr) |
| NO (1) | NO811161L (fr) |
| NZ (1) | NZ196829A (fr) |
| PH (1) | PH16264A (fr) |
| PL (1) | PL134762B1 (fr) |
| PT (1) | PT72881B (fr) |
| SE (1) | SE8002910L (fr) |
| ZA (1) | ZA811729B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7810947L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
| US4710503A (en) * | 1985-02-07 | 1987-12-01 | Euroceltique S.A. | 6-thioxanthine derivatives |
| GB8618931D0 (en) * | 1986-08-02 | 1986-09-10 | Euro Celtique Sa | 6-thioxanthines |
| US5298508A (en) * | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
| JP2843634B2 (ja) * | 1989-03-06 | 1999-01-06 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| IT1229195B (it) * | 1989-03-10 | 1991-07-25 | Poli Ind Chimica Spa | Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche. |
| WO1990012797A1 (fr) * | 1989-04-19 | 1990-11-01 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Derives de xanthene contenant du soufre comme antagonistes d'adenosine |
| CA2030112A1 (fr) * | 1989-11-24 | 1991-05-25 | Yasuo Ito | Compose de xanthine, methode de preparation et composition pharmaceutique contenant ledit compose |
| US5366977A (en) * | 1992-09-29 | 1994-11-22 | The United States Of America, As Represented By The Department Of Health And Human Services | Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners |
| DE4311538C1 (de) * | 1993-04-07 | 1994-10-06 | Boehringer Ingelheim Kg | Verfahren zur Herstellung von 1,3-Dimethyl-4,5-diaminouracil |
| WO1994025462A1 (fr) * | 1993-05-03 | 1994-11-10 | The United States Of America, Represented By The | Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite |
| US6316423B1 (en) | 1996-04-10 | 2001-11-13 | The United States Of America As Represented By The Departmant Of Health And Human Services | Method of treating ischemic, hypoxic and anoxic brain damage |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53890B2 (fr) * | 1972-04-22 | 1978-01-12 | ||
| CA1077932A (fr) * | 1976-03-31 | 1980-05-20 | Berlex Laboratories, Inc. | Composes de la xanthine pour le traitement des bronchospasmes et des affections allergiques |
| US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
| SE416810C (sv) * | 1977-10-14 | 1982-07-19 | Draco Ab | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet |
| SE7810947L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
| SE7810946L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
-
1980
- 1980-04-18 SE SE8002910A patent/SE8002910L/xx not_active Application Discontinuation
-
1981
- 1981-03-09 EP EP81850039A patent/EP0038784B1/fr not_active Expired
- 1981-03-09 AT AT81850039T patent/ATE10099T1/de not_active IP Right Cessation
- 1981-03-09 DE DE8181850039T patent/DE3166893D1/de not_active Expired
- 1981-03-16 ZA ZA00811729A patent/ZA811729B/xx unknown
- 1981-03-17 CA CA000373230A patent/CA1156229A/fr not_active Expired
- 1981-04-01 PH PH25455A patent/PH16264A/en unknown
- 1981-04-03 NO NO811161A patent/NO811161L/no unknown
- 1981-04-08 IE IE769/81A patent/IE51106B1/en unknown
- 1981-04-14 DD DD81229229A patent/DD158400A5/de unknown
- 1981-04-14 DK DK168281AA patent/DK151631B/da active IP Right Grant
- 1981-04-15 ES ES501400A patent/ES8203088A1/es not_active Expired
- 1981-04-15 NZ NZ196829A patent/NZ196829A/en unknown
- 1981-04-15 AU AU69555/81A patent/AU543122B2/en not_active Ceased
- 1981-04-15 GR GR64702A patent/GR82347B/el unknown
- 1981-04-16 PT PT72881A patent/PT72881B/pt unknown
- 1981-04-16 FI FI811212A patent/FI69465C/fi not_active IP Right Cessation
- 1981-04-17 JP JP5724181A patent/JPS56166191A/ja active Pending
- 1981-04-17 PL PL1981230737A patent/PL134762B1/pl unknown
- 1981-04-17 HU HU811020A patent/HU185254B/hu unknown
-
1983
- 1983-08-16 US US06/523,731 patent/US4546182A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO811161L (no) | 1981-10-19 |
| AU6955581A (en) | 1981-10-22 |
| PL134762B1 (en) | 1985-09-30 |
| PL230737A1 (fr) | 1982-03-29 |
| JPS56166191A (en) | 1981-12-21 |
| ES501400A0 (es) | 1982-02-16 |
| NZ196829A (en) | 1984-12-14 |
| DE3166893D1 (en) | 1984-12-06 |
| DK151631B (da) | 1987-12-21 |
| PT72881A (en) | 1981-05-01 |
| HU185254B (en) | 1984-12-28 |
| IE51106B1 (en) | 1986-10-01 |
| EP0038784B1 (fr) | 1984-10-31 |
| DD158400A5 (de) | 1983-01-12 |
| PT72881B (en) | 1983-03-29 |
| EP0038784A2 (fr) | 1981-10-28 |
| ES8203088A1 (es) | 1982-02-16 |
| GR82347B (fr) | 1984-12-13 |
| AU543122B2 (en) | 1985-04-04 |
| PH16264A (en) | 1983-08-23 |
| SE8002910L (sv) | 1981-10-19 |
| FI811212L (fi) | 1981-10-19 |
| EP0038784A3 (en) | 1982-01-20 |
| DK168281A (da) | 1981-10-19 |
| CA1156229A (fr) | 1983-11-01 |
| ZA811729B (en) | 1982-04-28 |
| FI69465B (fi) | 1985-10-31 |
| US4546182A (en) | 1985-10-08 |
| IE810796L (en) | 1981-10-18 |
| ATE10099T1 (de) | 1984-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0010531B1 (fr) | Alcoyl-3-xanthines, procédés pour leur préparation et compositions utilisables dans le traitement de maladies chroniques des voies respiratoires et de maladies cardiaques | |
| EP0011609B1 (fr) | Dérivés de xanthine et préparation pharmaceutique les contenant pour utilisation dans le traitement de maladies chroniques d'obstruction des voies respiratoires et de maladies cardiaques | |
| FI66383C (fi) | Foerfarande foer framstaellning av farmakologiskt aktiva xantinderivat | |
| ES2222614T3 (es) | Derivados de purina y medicina que los contiene como ingrediente activo. | |
| FI69465C (fi) | Foerfarande foer framstaellning av farmakologiskt aktiva 3,8-dialkylxantiner | |
| US4612315A (en) | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives | |
| US6310205B1 (en) | Hypoxathine compounds | |
| CN102791707A (zh) | {4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的制备方法以及为了将其用作药用活性成分的纯化方法 | |
| DK161965B (da) | 6-thioxanthiner og salte deraf samt deres fremstilling og anvendelse | |
| HU203755B (en) | Process for producing cyclopenentyl-purine derivatives and pharmaceutical compositions containing them | |
| AU8034800A (en) | Selective antagonists of A2B adenosine receptors | |
| JPH0755949B2 (ja) | 新規ピリド〔２，３−ｄ〕ピリミジン誘導体、その製造方法並びに該化合物を含有する医薬組成物 | |
| CN116041349B (zh) | 一种黄嘌呤类化合物及其制备方法和在制备新冠病毒3cl蛋白酶抑制剂中的应用 | |
| JPH02164881A (ja) | 治療用ヌクレオシド化合物 | |
| HU180321B (en) | Process for producing 6- and 9-substituted 2-amino-purine derivatives | |
| JPH06293762A (ja) | ピリド〔２，３−ｄ〕ピリミジン誘導体を含有する医薬組成物 | |
| CH670090A5 (fr) | ||
| JPH05262770A (ja) | 化学的製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: AKTIEBOLAGET DRACO |